ReviewMolecular psychiatry2026
Beyond the sugar coating: mucin-type O-Glycosylation as an underappreciated player in brain function and disease.
Review in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Mucin-type O-glycosylation (O-GalNAcylation) is a structurally diverse post-translational modification (PTM) that serves as a critical molecular interface at the cell surface. Unlike well-characterized PTMs such as phosphorylation or N-glycosylation, the specific roles of O-GalNAcylation in the mammalian brain have long remained poorly understood. Recent studies have begun to reposition this modification as an important regulator of brain architecture and homeostasis. Emerging evidence suggests that it contributes to neuronal organization, neurovascular integrity, synaptic function, and stress-related behavioral phenotypes, and that its dysregulation may be associated with neurological and psychiatric phenotypes. This perspective synthesizes recent advances to highlight the potential importance of a "brain O-glycan code" in brain health and disease. We discuss how remodeling of this glycan landscape may intersect with aging, neuroinflammation, and synaptic plasticity, and propose that glyco-neurobiology provides an additional conceptual layer for understanding brain vulnerability and resilience. Finally, we consider how targeting O-glycosylation pathways may open new avenues for diagnostic and therapeutic strategies in neurodegenerative and psychiatric disease.
Identifiers
42547803What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.